Al­ler­gan bags an ear­ly-stage gene ther­a­py in $60M Ret­roSense buy­out

While Al­ler­gan’s ac­quis­i­tive CEO Brent Saun­ders was map­ping out a new com­mit­ment to shun preda­to­ry pric­ing, he si­mul­ta­ne­ous­ly threw in the lat­est in a se­ries of bolt-on buy­outs.

This time, Saun­ders has de­cid­ed to pay $60 mil­lion up front to ac­quire a small gene ther­a­py play­er based in Ann Ar­bor, MI. Ret­roSense Ther­a­peu­tics has been at­tract­ing at­ten­tion for its work us­ing a gene ther­a­py to re­store light sen­si­tiv­i­ty to the reti­na in an at­tempt to re­store the sight of peo­ple who have been blind­ed by re­tini­tis pig­men­tosa.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.